Is the Sirolimus encapsulated balloon a reliable tool for treating the in-stent restenosis?—insights from the SABRE trial

The introduction of drug-eluting stents (DES), has positively changed of the outcomes of percutaneous coronary interventions (PCI), due to the dramatically decreased incidence of in-stent restenosis (ISR) (1). The overall improvement in safety profile of drug-eluting and newer generation DES, due to advancement in technology, platform, polymer and type of drug have pushed the interventionalist to treat more complex patients and coronary stenoses (2,3). Accordingly, the latest European Guidelines on Myocardial Revascularization (4) state that DES should be considered as first line choice in all patients and coronary lesion subsets